| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Cytarabine | GDSC1000 | pan-cancer | AAC | -0.049 | 0.2 |
| mRNA | linifanib | CTRPv2 | pan-cancer | AAC | -0.049 | 0.2 |
| mRNA | ciclopirox | CTRPv2 | pan-cancer | AAC | -0.045 | 0.2 |
| mRNA | CAY10618 | CTRPv2 | pan-cancer | AAC | 0.047 | 0.2 |
| mRNA | BCL-LZH-4 | CTRPv2 | pan-cancer | AAC | -0.074 | 0.2 |
| mRNA | PF-4800567 hydrochloride | CTRPv2 | pan-cancer | AAC | -0.074 | 0.2 |
| mRNA | Vandetanib | CTRPv2 | pan-cancer | AAC | -0.048 | 0.2 |
| mRNA | EX-527 | GDSC1000 | pan-cancer | AAC | -0.046 | 0.2 |
| mRNA | narciclasine | CTRPv2 | pan-cancer | AAC | -0.043 | 0.2 |
| mRNA | KU-60019 | CTRPv2 | pan-cancer | AAC | -0.046 | 0.2 |